PCSK9 and familial hypercholesterolemia: In addition, the PCSK9 siRNA drug, inclisiran, has been successively approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration for the reduction of cholesterol levels in patients with primary hypercholesterolemia or mixed dyslipidemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease (Dec et al. 2023).